Item 7.01 Regulation FD Disclosure. On November 9, 2020, Genocea Biosciences, Inc. issued a press release announcing four posters highlighting clinical and preclinical data that collectively validate the company's unique and differentiated approach to identifying clinically meaningful immunotherapy targets at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting taking place virtually November 9th - 14th. A copy of the press release, dated November 9, 2020, is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing.




Item 9.01  Financial Statements and Exhibits.
(d) Exhibits

  99.1      Press Release issued by Genocea Biosciences, Inc. on November 9, 2020

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses